Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $10.67 Average PT from Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received a consensus rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, eleven have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $10.6667.

TSHA has been the subject of a number of research analyst reports. UBS Group set a $11.00 price target on Taysha Gene Therapies in a research report on Thursday, December 4th. Wall Street Zen lowered Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. Raymond James Financial reiterated a “strong-buy” rating and set a $13.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Citizens Jmp boosted their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “market outperform” rating in a report on Wednesday, November 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $10.00 price objective on shares of Taysha Gene Therapies in a report on Friday, October 17th.

Taysha Gene Therapies Stock Down 1.3%

Taysha Gene Therapies stock opened at $4.51 on Friday. Taysha Gene Therapies has a fifty-two week low of $1.05 and a fifty-two week high of $6.02. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48. The firm’s 50-day simple moving average is $5.12 and its 200 day simple moving average is $4.13. The stock has a market cap of $1.24 billion, a PE ratio of -13.67 and a beta of 1.01.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. Research analysts predict that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Insider Activity

In other news, insider Sukumar Nagendran sold 260,047 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $4.51, for a total transaction of $1,172,811.97. Following the completion of the sale, the insider owned 1,006,439 shares in the company, valued at $4,539,039.89. This trade represents a 20.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Kamran Alam sold 78,968 shares of Taysha Gene Therapies stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $4.75, for a total transaction of $375,098.00. Following the completion of the sale, the chief financial officer directly owned 1,467,635 shares in the company, valued at $6,971,266.25. This trade represents a 5.11% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 967,140 shares of company stock valued at $4,510,613 in the last three months. Company insiders own 3.78% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. ST Germain D J Co. Inc. increased its holdings in Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after acquiring an additional 4,333 shares during the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in Taysha Gene Therapies during the third quarter valued at about $40,000. Marex Group plc bought a new position in Taysha Gene Therapies during the second quarter worth about $29,000. E Fund Management Co. Ltd. purchased a new position in shares of Taysha Gene Therapies in the second quarter worth about $31,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Taysha Gene Therapies by 26.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,311 shares of the company’s stock valued at $73,000 after purchasing an additional 2,765 shares during the period. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.